01 4Tislelizumab
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 281
2020 Revenue in Millions : 178
Growth (%) : 56
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 446
2021 Revenue in Millions : 281
Growth (%) : 59
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 581
2022 Revenue in Millions : 446
Growth (%) : 27
Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 621
2023 Revenue in Millions : 537
Growth (%) : 16
